An AI health-tech startup recently named one of the world's most promising had its roots in the re-organisation of Xerox's research centre in India
In a Delaware case Boehringer Ingelheim accuses the Illinois company of improper conduct in deliberately constructing a patent thicket to protect against generic versions of its blockbuster drug.
With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent
Former IV unit teams up with alternative asset business to give large and small innovators way of attracting finance on Blockchain-based initiative
Coherus launched Delaware action against Amgen in what is likely to become an increasingly familiar life sciences litigation scenario.
PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies
Increased R&D outsourcing and patent licensing account for pharma’s diminishing representation among the world’s top 100 innovators, while technological diversification may also be playing its part
As fears grow over subject-matter eligibility and technological convergence threatens to reshape the competitive landscape, patent strategy has become even more crucial for medical device companies
The court’s decision in Helsinn Healthcare v Teva Pharmaceutical will disappoint the many biopharma businesses that depend on pre-marketing drug development collaboration
Given the difficulty that pharmaceutical products face when it comes to reaching market, Arrow declarations can be a crucial means of slicing through the knot.
Appointment of experienced patent litigator to local bench and Austin's growing reputation as a tech hub must be weighed against defendant-friendly rules
Draft changes would entitle women inventors and small businesses to expedited patent examination, but some see a backdoor for big business to take advantage too
Services at the FDA could “grind to a halt” in a matter weeks if the budget deadlock between President Trump and Democrats continues. Major disruption at the USPTO and in the courts may also be on the cards.
Lawsuit filings and inter partes review petitions both fell in 2018, but operating companies’ share of the action was on the rise
New report shows research institutions dominate the field, with UCAL, Johns Hopkins, Stanford, the NIH, Harvard and Singapore’s Agency for Science Technology & Research leading the way between 2015 and 2018